-- Net Loss
Net loss for the second quarter 2013 was €4.7 million in the second quarter
2013 and €8.2 million for the six months ended June 30, 2013, compared to
€2.4 million and €5.1 million for the comparable periods in 2012.
Near-Term News Flow
In the fourth quarter 2013, GSK aims to make available and present
dystrophin results from the DMD114117 (DEMAND II) study as well as results
from the DMD114044 (DEMAND III) and DMD114876 (DEMAND V) studies at
forthcoming scientific meetings.
In the third quarter 2013, Prosensa anticipates the first patient to be
dosed with PRO053 in the phase I/II safety and dose finding study which is
currently in the recruitment screening phase.
In the fourth quarter 2013, results from the phase I/II study will be
presented at forthcoming scientific meetings.
Conference Call / Webcast Information
Prosensa will host a conference call on Wednesday, August 28, 2013 at 8:00am
ET, 2:00pm CET to discuss second quarter 2013 financial results. In order to
participate in the conference call, please dial 1-877-249-9037 (US domestic)
and refer to conference ID 6727193. International dial-in numbers and an audio
webcast can be accessed under "Events & Presentations" through the Investors &
Media section of the Prosensa corporate website www.prosensa.com.
About Prosensa Holding N.V.
Prosensa (Nasdaq:RNA) is an innovative biotechnology company engaged in the
discovery and development of ribonucleic acid-modulating, or RNA-modulating,
therapeutics for the treatment of genetic disorders. Our primary focus is on
rare neuromuscular and neurodegenerative disorders with a large unmet medical
need, including Duchenne muscular dystrophy, myotonic dystrophy and
Huntington's disease. Our clinical portfolio of RNA-based product candidates is
focused on the treatment of Duchenne muscular dystrophy, or DMD. Each of our
DMD compounds has been granted orphan drug status in the United States and the
European Union. Our first product candidate, drisapersen, can address a variety
of mutations in the dystrophin gene, such as a deletion of exon 50 or exons 48
DMD is one of the most prevalent rare genetic diseases globally affecting up to
1 in 3,500 boys and is invariably fatal. There is currently no approved
disease-modifying therapy for DMD. The progressive muscle-wasting that
characterizes this disease is caused by inadequate production of dystrophin, a
protein necessary for muscle function, as a result of mutations in the
dystrophin gene. The different mutations, which are mostly deletions of one or
more exons, found in the dystrophin gene result in distinct sub-populations of
DMD patients. We are designing product candidates to address several
sub-populations using our platform technology.
About exon skipping and RNA modulation
The dystrophin gene is the largest gene in the body, consisting of 79 exons.
Exons are small sequences of genetic code which, via an intermediate step
involving RNA, lead to the assembly of sections of protein. In DMD, when
certain exons are mutated/deleted, the RNA cannot read past the fault. This
prevents the remainder of the exons from being read, resulting in a
non-functional dystrophin protein and the severe symptoms of DMD. RNA-based
therapeutics, specifically antisense oligonucleotides inducing exon skipping,
are currently in development for DMD. These antisense oligonucleotides skip an
exon next to a defective exon and thereby correct the reading frame, enabling
the production of a novel, largely functional dystrophin protein. Prosensa's
exon skipping technology was licensed from Leiden University Medical Center.
Forward Looking Statement
This press release contains certain forward-looking statements. All statements,
other than statements of historical facts, contained in this press release,
including statements regarding our strategy, future operations, future
financial position, future revenues, projected costs, prospects, plans and
objectives of management, are forward-looking statements. The words
"anticipate," "believe," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain
these identifying words. Forward-looking statements in this press release
include statements around our exon-skipping drug pipeline and financial
position. Actual results may differ materially from those projected or implied
in such forward-looking statements. Such forward-looking information involves
risks and uncertainties that could significantly affect expected results. These
risks and uncertainties are discussed in the Company's SEC filings, including,
but not limited to, the Company's Form 6-K containing this press release and
certain sections of the Company's Registration Statement on Form F-1. In
addition, any forward-looking statements represent our views only as of today
and should not be relied upon as representing our views as of any subsequent
date. While we may elect to update these forward-looking statements at some
point in the future, we specifically disclaim any obligation to do so, even if
our views change.
CONTACT: Prosensa Holding N.V.Celia Economides, Director IR & Corporate Communications
Phone: +1 917 941 9059
Copyright © 2013 OMX AB (publ).